Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sab Biotherapeutics Inc WT (NQ: SABSW ) 0.0628 -0.0072 (-10.29%) Streaming Delayed Price Updated: 3:49 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,710 Open 0.0502 Bid (Size) 0.0500 (25) Ask (Size) 0.1800 (100) Prev. Close 0.0700 Today's Range 0.0502 - 0.0628 52wk Range 0.0100 - 0.1888 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update November 06, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference October 31, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Performance YTD +192.09% +192.09% 1 Month +67.47% +67.47% 3 Month +68.36% +68.36% 6 Month +57.00% +57.00% 1 Year +1.13% +1.13% More News Read More SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference September 13, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting September 09, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting September 04, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates August 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes August 05, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB BIO Appoints Lucy To as Chief Financial Officer July 31, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAb Biotherapeutics Rebrands as SAB BIO June 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions June 18, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Departure of Chief Financial Officer May 30, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics May 21, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates May 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors May 06, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Provides SAB-142 Trial Update April 16, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at INNODIA Annual Meeting April 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference April 04, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment March 25, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the BIO CEO & Investor Conference February 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Executive Leadership Change February 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement January 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split January 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes November 29, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors November 20, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
